Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Sunday, December 4, 2016

Lemtrada Lessens MS Disability in People Who Respond Poorly to Other Therapies, Study Says


                                                                  
  

Click here to receive MS news via e-mail



Data from the CARE-MS II clinical trial showed that Lemtrada(alemtuzumab) can lessen pre-existing disabilities in patients with relapsing-remitting multiple sclerosis (RRMS) who failed to respond adequately to previous disease-modifying therapies, according to a study of the trial’s data. The treatment was evaluated against Rebif(interferon beta-1a) therapy.
A major aim of multiple sclerosis (MS) treatment is limiting patients’ disability, an outcome usually measured by the delay in confirmed disability worsening (CDW). However, interest in growing in efforts to reach confirmed disability improvement (CDI), a higher standard of therapeutic efficacy than that of slowing disability accumulation.
CDI is believed to reflect durable and clinically meaningful Expanded Disability Status Scale (EDSS) score changes. EDSS is a standard method of quantifying disability in MS.
In this study, the researchers’ objective was to characterize the effects of Lemtrada treatment on measures of disability improvement in patients with RRMS whose response to other treatments was found to be inadequate (relapsing at least once). Lemtrada is a humanized monoclonal antibody capable of remodeling the immune responses of innate immune cells in patients with RRMS.




MS Views and News
Providing educational information, resources and services for those affected by MS
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: